ストックスクリーナーアプリを入手
72.14
0.37%
0.265
アフターアワーズ：
72.14
0.005
+0.01%
前日終値:
$71.87
開ける：
$71.96
24時間の取引高:
2.94M
Relative Volume:
0.64
時価総額：
$10.87B
収益：
$10.73M
当期純損益:
$-455.74M
株価収益率:
-20.28
EPS:
-3.5569
ネットキャッシュフロー:
$-502.70M
1週間 パフォーマンス:
+0.75%
1か月 パフォーマンス:
+1.81%
6か月 パフォーマンス:
+146.03%
1年 パフォーマンス:
+134.97%
1日の値動き範囲:
$71.96
$72.20
1週間の範囲:
$71.52
$72.20
52週間の値動き範囲:
$21.51
$72.20
Avidity Biosciences Inc Stock (RNA) Company Profile
名前
Avidity Biosciences Inc
セクター
電話
858-401-7900
住所
3020 CALLAN ROAD, SAN DIEGO, CA
RNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
72.14 | 10.83B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-17 | 開始されました | Roth Capital | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-06-24 | 開始されました | Bernstein | Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-06-11 | 開始されました | Raymond James | Strong Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-09-24 | 開始されました | Goldman | Buy |
| 2024-08-28 | 開始されました | Barclays | Overweight |
| 2024-05-03 | 開始されました | BofA Securities | Buy |
| 2024-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-05-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-31 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Strong Buy |
| 2021-09-07 | 開始されました | Evercore ISI | Outperform |
| 2021-06-17 | 開始されました | Needham | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | Cowen | Outperform |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-07-07 | 開始されました | SVB Leerink | Outperform |
| 2020-07-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Avidity Biosciences Inc (RNA) 最新ニュース
Novartis-Avidity Biosciences deal gets early clearance in US - MLex
Avidity reports FTC granted request for early termination of HSR waiting period - TipRanks
Evercore ISI Downgrades Avidity Biosciences to In Line From Outperform, Adjusts Price Target to $72 From $65 - marketscreener.com
Avidity Biosciences Receives FTC Clearance for Novartis Merger - TipRanks
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week HighHere's Why - MarketBeat
Is Avidity Biosciences Inc. stock resilient to inflation2025 Key Highlights & Real-Time Price Movement Reports - Bollywood Helpline
Mirador Capital Partners LP Purchases 22,666 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences (NASDAQ: RNA) advances Novartis merger and revises executive pay - Stock Titan
Top 2 Health Care Stocks That May Keep You Up At Night In December - Benzinga
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity - MSN
Frazier Life Sciences Management L.P. Has $17.75 Million Stock Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Reaches New 52-Week HighWhat's Next? - MarketBeat
EcoR1 Capital LLC Sells 57,576 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences stock hits all-time high at 71.81 USD By Investing.com - Investing.com Australia
Avidity Biosciences stock hits all-time high at 71.81 USD - Investing.com
Aug Closing: Is Avidity Biosciences Inc stock vulnerable to regulatory risksTrade Performance Summary & Growth-Oriented Investment Plans - moha.gov.vn
Avoiding Lag: Real-Time Signals in (RNA) Movement - news.stocktradersdaily.com
Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger - MSN
Assessing Avidity Biosciences (RNA) Valuation After a 130% Year-to-Date Share Price Surge - Yahoo Finance
Dyne stock upgraded at Oppenheimer (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says - marketscreener.com
Norges Bank Makes New Investment in Avidity Biosciences, Inc. $RNA - MarketBeat
Franklin Resources Inc. Sells 29,465 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
JPMorgan Chase & Co. Buys 139,473 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences stock hits all-time high at 71.78 USD By Investing.com - Investing.com South Africa
Avidity Biosciences stock hits all-time high at 71.78 USD - Investing.com
Why Avidity Biosciences Inc. stock could benefit from AI revolution2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - Newser
Avidity Biosciences, Inc. (RNA): A Bull Case Theory - Finviz
Schroder Investment Management Group Raises Stake in Avidity Biosciences, Inc. $RNA - MarketBeat
How Avidity Biosciences Inc. stock reacts to Fed rate cutsEarnings Overview Summary & AI Enhanced Trade Execution Alerts - Newser
Avidity Biosciences, Inc. $RNA Shares Sold by Steward Partners Investment Advisory LLC - MarketBeat
Avidity Biosciences, Inc. $RNA Shares Sold by Prudential Financial Inc. - MarketBeat
Will Avidity Biosciences Inc. stock outperform Dow Jones indexMarket Growth Report & Detailed Earnings Play Alerts - Newser
Creative Planning Grows Stock Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44 (PR Newswire) - Aktiellt
Discipline and Rules-Based Execution in RNA Response - news.stocktradersdaily.com
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 (PR Newswire) - Aktiellt
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society (PR Newswire) - Aktiellt
Update Recap: Can Avidity Biosciences Inc. stock sustain free cash flow growth2025 Risk Factors & Reliable Entry Point Alerts - BỘ NỘI VỤ
What analysts say about Avidity Biosciences Inc stockSwing Trading Watchlist & Investment Timing Techniques - earlytimes.in
SG Americas Securities LLC Raises Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire) - Aktiellt
Avidity Biosciences, Inc. $RNA Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis - MSN
Avidity Played Hardball to Land Favorable Terms in $12B Novartis Deal - BioSpace
Avidity Biosciences stock hits all-time high at 71.1 USD By Investing.com - Investing.com Nigeria
Avidity Biosciences stock hits all-time high at 71.1 USD - Investing.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Ensign Peak Advisors Inc Purchases 200,836 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Artisan Partners Limited Partnership Has $25.05 Million Stake in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences Inc (RNA) 財務データ
収益
当期純利益
現金流量
EPS
Avidity Biosciences Inc (RNA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hughes Steven George | Chief Medical Officer |
Oct 22 '25 |
Sale |
47.54 |
2,209 |
105,015 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Option Exercise |
22.34 |
20,000 |
446,800 |
117,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Sale |
50.15 |
20,000 |
1,003,058 |
97,130 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Option Exercise |
9.05 |
6,562 |
59,386 |
61,562 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Sale |
45.38 |
6,562 |
297,771 |
55,000 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Option Exercise |
10.16 |
2,208 |
22,433 |
41,075 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Sale |
40.58 |
2,208 |
89,601 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Option Exercise |
22.34 |
15,000 |
335,100 |
112,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Sale |
41.41 |
15,000 |
621,142 |
97,130 |
| Hughes Steven George | Chief Medical Officer |
Sep 15 '25 |
Option Exercise |
6.57 |
1,542 |
10,131 |
40,409 |
0.31%
0.33%
大文字化:
|
ボリューム (24 時間):